Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market to Surpass US$ 20,450.6 Million by 2030 - Coherent Market Insights

22 Jun 2022
www.prnewswire.com
AcquisitionCollaborate
SEATTLE, June 22, 2022 /PRNewswire/ -- According to
acute bacterial skin and skin structure infections (ABSSSI) market is estimated to be valued at
US$ 10,263.5 million in
2022 and is expected to exhibit a
CAGR of
9.0% over the forecast period
(2022-2030).
Key Trends and Analysis of the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market:
Key trends in market include widespread presence of acute bacterial skin and skin structure infections (ABSSSI); increasing approval of
novel drugs for acute bacterial skin and skin structure infections (ABSSSI), and increasing collaborations, acquisitions, and partnerships among key players. These key trends are expected to aid in growth of the global acute bacterial skin and skin structure infections (ABSSSI) market.
According to an article published in the PLOS One journal, a peer-reviewed open access scientific journal in July 2020, the lifetime prevalence of skin and soft tissue infections (SSTI), a type of ABSSSI in people who inject drugs (PWID) in London was found to be 64% (abscess and/or cellulitis), on the basis of data collected between October 2017 and March 2019.
Moreover, rapid research and development in the field of
acute bacterial skin and skin structure infections (ABSSSI) for development of novel treatment for the same is expected to fuel market growth over the forecast period. For instance, in January 2022, Paladin Labs Inc., a subsidiary of Endo International plc launched Xydalba (dalbavancin for injection), in Canada. Xydalba is a 30-minute intravenous (IV) therapy, which can be administered as a single- or two-dose regimen for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
Furthermore, key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market are focusing on adoption of inorganic growth strategies such as partnerships, acquisitions, collaborations, and others in order to expand their market presence in the global market. For instance, in May 2020, Advanz Pharma, a U.K.-based pharmaceutical company, announced that it had completed the acquisition of Correvio Pharma Corp., a Canada-based specialty pharmaceutical company whose product portfolio includes licensed medicines such as XYDALBA (dalbavancin hydrochloride) indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1531
Key Market Takeaways:
Global
acute bacterial skin and skin structure infections (ABSSSI) market is expected to exhibit a CAGR of 9.0% over the forecast period, owing to rising focus of market players on regulatory approvals for novel acute bacterial skin and skin structure infections (ABSSSI) therapeutics. For instance, in July 2021, AbbVie Inc. ., a U.S. based pharmaceutical company announced that it has received the U.S. Food and Drug Administration (USFDA) approval for its drug Dalvance (dalbavancin), administered as an intravenous (IV) infusion for the treatment of pediatric patients with ABSSSI caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
Among infection type, community acquired ABSSSI segment is expected to account for the largest market share in 2022, owing to rising drug launches by market players for treatment of community acquired acute bacterial skin and skin structure infections (ABSSSI). For instance, in February 2021, Paratek Pharmaceuticals, Inc., a U.S.-based pharmaceutical company announced that it is expanding commercial launch of its tetracycline-class oral antibiotic Nuzyra (omadacycline) into the community setting. Nuzyra is indicated for the treatment of adults with acute skin and skin structure infections (ABSSSI).
Key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market include
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1531
Detailed Segmentation:
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type:
Oral & Parenteral Antibiotics
Vancomycin
Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type:
Hospital Acquired ABSSSI
Community Acquired ABSSSI
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration:
Oral
Topical
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region:
North America
By Country:
U.S.
Canada
Europe
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East & Africa
By Country:
GCC Countries
Israel
South Africa
Rest of Middle East & Africa
Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/1531
Find related trending report below:
North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
, by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
SOURCE Coherent Market Insights
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.